\nComitetul pentru siguran\u0163a medicamentelor (PRAC) al EMA a lansat \u00een ianuarie o revizuire a medicamentelor care con\u0163in semaglutid – ingredientul activ din Ozempic, Wegovy \u015fi Rybelsus de la Novo Nordisk – \u00een urma \u00eengrijor\u0103rilor c\u0103 medicamentele ar putea duce la un risc crescut de apari\u0163ie a neuropatiei optice ischemice anterioare nearteriale (NAION).<\/p>\n
\nNAION este o afec\u0163iune cauzat\u0103 de reducerea fluxului sanguin c\u0103tre nervul optic din ochi, care poate deteriora nervul \u015fi duce la pierderea permanent\u0103 a vederii, scrie Politico.<\/p>\n
\nPRAC a declarat c\u0103 a constatat c\u0103 afec\u0163iunea este \u201eun efect secundar foarte rar\u201d al semaglutidei, put\u00e2nd afecta una din 10.000 de persoane care iau medicamentul. EMA a declarat c\u0103 expunerea la semaglutid la persoanele cu diabet zaharat este legat\u0103 de o cre\u015ftere de dou\u0103 ori a riscului de a dezvolta NAION \u00een compara\u0163ie cu persoanele care nu iau medicamentul.<\/p>\n
\nAutoritatea de reglementare a solicitat ca informa\u0163iile despre produs pentru medicamentele cu semaglutid s\u0103 fie actualizate pentru a include NAION ca efect secundar cu o frecven\u0163\u0103 \u201efoarte rar\u0103\u201d. Decizia final\u0103 trebuie aprobat\u0103 de Comisia European\u0103.<\/p>\n","protected":false},"excerpt":{"rendered":"
Pacien\u0163ii care iau medicamentele pentru diabet \u015fi pierdere \u00een greutate Wegovy \u015fi Ozempic au un risc crescut de a dezvolta o afec\u0163iune ocular\u0103 rar\u0103 care ar putea duce la pierderea vederii, anun\u0163\u0103 vineri Agen\u0163ia European\u0103 pentru Medicamente (EMA).<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[511],"tags":[15493,323,322],"class_list":["post-237218","post","type-post","status-publish","format-standard","hentry","category-afaceri","tag-diabet","tag-medicamente","tag-ozempic"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/237218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=237218"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/237218\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=237218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=237218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=237218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}